Metastatic Cancer Survival Gains Vary by Malignancy Type Edited by Katie Lennon May 08, 2026

https://www.medscape.com/viewarticle/metastatic-cancer-survival-gains-vary-malignancy-type-2026a1000etu Five-year overall survival (OS) for patients with de novo metastatic cancer increased from 10.6% in 1976-1981 to 23.6% in 2015-2020, representing more than a twofold improvement. Survival gains were largest in breast cancer (12.6% to 34.2%), hematologic malignancies (24.3% to 53.9%), and colorectal cancer (3.7% to 15.0%), whereas pancreatic and small cell lung cancers showed minimal improvement.